Health & Pharm General

Nyrada Inc (ASX:NYR) 57% Reduction in Total Cholesterol from Nyrada's NYX-PCSK9i In Vivo Study

🕔12/21/2020 10:20:51 AM

Nyrada Inc (ASX:NYR) is pleased to report encouraging efficacy results from its cholesterol-lowering drug program which is directed at developing an oral PCSK9 inhibitor treatment for hypercholesterolemia (high cholesterol).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Human Health Update

🕔12/8/2020 8:57:08 AM

Anatara Lifesciences (ASX:ANR) is pleased to advise that it is planning initiation of a human clinical study on changes to psychological functioning in adults with a moderate level of depression, anxiety or stress symptoms, in response to use of the Company's recently developed colon-targeted formulation (3FDC).

Read Full Article

Bluechiip Ltd (ASX:BCT) Annual General Meeting - CEO's Presentation

🕔11/27/2020 8:46:43 AM

Bluechiip Ltd (ASX:BCT) has a world first, highly differentiated technology, with protected IP and a $200M growing target market, with very large adjacent markets.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Chairman's Address to Shareholders and Presentation

🕔11/26/2020 10:51:01 AM

The last twelve months have seen exciting developments as Anatara Lifesciences Ltd (ASX:ANR) advances our lead human health product, our Gastrointestinal ReProgramming (GaRP) complementary medicine.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Animal Health Update

🕔11/18/2020 8:52:00 AM

Anatara Lifesciences (ASX:ANR) is pleased to provide an update on challenge trials of select Anatara animal health assets.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) $1.4m Raised Through the Completed SPP

🕔11/16/2020 2:26:07 PM

Anatara Lifesciences (ASX:ANR) is pleased to advise that the Share Purchase Plan (SPP) announced to the market on 21 October 2020 closed on 11 November 2020 oversubscribed.

Read Full Article

AusCann Group Holdings Ltd (ASX:AC8) and CannPal Enter Into Scheme of Arrangement

🕔11/16/2020 12:10:39 PM

AusCann Group Holdings Ltd (ASX:AC8), an Australian based pharmaceutical company focused on the development, production and distribution of cannabinoid-based medicines within Australia and internationally, is pleased to announce that it has entered into a scheme implementation deed (SID) with CannPal Animal Therapeutics Limited.

Read Full Article